Leerink Partnrs Has Bearish Forecast for Geron Q2 Earnings

Geron Co. (NASDAQ:GERN - Free Report) - Equities researchers at Leerink Partnrs lowered their Q2 2025 earnings estimates for Geron in a report issued on Monday, April 21st. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings per share of ($0.04) for the quarter, down from their prior forecast of ($0.03). The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron's Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.17) EPS and FY2026 earnings at ($0.02) EPS.

A number of other research analysts have also commented on GERN. HC Wainwright reiterated a "neutral" rating on shares of Geron in a report on Wednesday, March 12th. Scotiabank reduced their target price on shares of Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price target on shares of Geron in a report on Wednesday, March 12th. Barclays reaffirmed an "overweight" rating and issued a $4.00 target price (down from $9.00) on shares of Geron in a research report on Thursday, February 27th. Finally, Stifel Nicolaus lowered their price target on shares of Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $5.75.

Geron Stock Down 1.8 %

Shares of GERN traded down $0.03 during trading hours on Wednesday, hitting $1.40. 2,729,298 shares of the company were exchanged, compared to its average volume of 11,472,910. The firm's 50 day moving average is $1.64 and its 200-day moving average is $2.91. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a 52 week low of $1.17 and a 52 week high of $5.34. The company has a market cap of $888.49 million, a PE ratio of -4.36 and a beta of 0.66.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million.

Institutional Trading of Geron

Institutional investors and hedge funds have recently made changes to their positions in the business. Nvest Financial LLC bought a new stake in Geron in the fourth quarter valued at about $693,000. Charles Schwab Investment Management Inc. increased its stake in shares of Geron by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,523,864 shares of the biopharmaceutical company's stock valued at $16,014,000 after acquiring an additional 73,482 shares during the last quarter. Barclays PLC raised its position in shares of Geron by 114.9% in the 3rd quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company's stock valued at $5,902,000 after acquiring an additional 694,931 shares during the period. Renaissance Technologies LLC bought a new position in Geron during the 4th quarter worth approximately $5,143,000. Finally, World Investment Advisors LLC grew its holdings in Geron by 10,151.4% during the third quarter. World Investment Advisors LLC now owns 1,029,553 shares of the biopharmaceutical company's stock valued at $4,674,000 after purchasing an additional 1,019,510 shares during the period. Institutional investors own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.